Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6262123 | 0.79 | SRD5A2 (0.47) | MAPTKMT2ARAB9AMEN1ALDH1A1 | |
| SCHEMBL6255790 | 0.78 | RAB9A (0.51) | PDE10AMAPTKMT2ALMNARAB9A | |
| SCHEMBL6255333 | 0.77 | HDAC1 (0.44) | KMT2ALMNAMEN1MAPK1NPSR1 | |
| SCHEMBL6260691 | 0.76 | RAB9A (0.52) | MAPTKMT2ALMNARAB9AMEN1 | |
| SCHEMBL6258754 | 0.75 | MAPT (0.52) | MAPTKMT2ALMNARAB9AMEN1 | |
| SCHEMBL6259938 | 0.75 | MAPT (0.52) | MAPTKMT2ALMNARAB9AMEN1 | |
| SCHEMBL6255143 | 0.74 | CYP3A4 (0.50) | KMT2ARAB9AMEN1MAPK1NPC1 | |
| SCHEMBL1445542 | 0.74 | CNR2 (0.67) | PDE10AKMT2ARAB9AHPGDNPSR1 | |
| SCHEMBL5806328 | 0.73 | CA1 (0.50) | PDE10AMAPTKMT2ALMNARAB9A | |
| SCHEMBL3195451 | 0.72 | KMT2A (0.58) | MAPTKMT2ALMNARAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| EP-0999834-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6586459-B2 | Inhibitors of factor Xa; for example 3-(4-tert-butylbenzoyl)amino-N-(4-methoxyphenyl)-2-thiophenecarboxamide | BEIGHT DOUGLAS WADE (US) | 2003-07-01 | — | — | US | disclosed |
| US-6583173-B2 | Useful as anticoagulants in mammals; inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-06-24 | — | — | US | disclosed |
| US-20020072531-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-06-13 | — | — | US | disclosed |
| US-20020049234-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-04-25 | — | — | US | disclosed |
| US-6313151-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-0999834-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-0999834-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999000126-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062271-A1 | Antithrombotic Diamides | TFPI, SERPINC1, TFPI2 | PDE10A 97/4885MAPT 4436/4885KMT2A 4224/4885 |
| US-20020072531-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | PDE10A 264/4885MAPT 4730/4885KMT2A 4505/4885 |
| US-20020049234-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | PDE10A 264/4885MAPT 4730/4885KMT2A 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.